Fig. 4.

a) Heatmap showing high variability in genes involved in Proliferation, Hypoxia and Angiogenesis signatures. Each row represents a gene and each column represents single patient. Colors reflect the fold change for each gene post-bevacizumab. With whole cohort of study patients (n = 36), significant global down-regulation of the proliferation signature (paired t-test: t = − 2.09, P-value = 0.04) but no significant change in the specific breast cancer hypoxia signature (paired t-test: t = − 0.20, P-value = 0.84), angiogenesis signature (paired t test: t = 0.81, P-value = 0.42). b) IHC sections showing significant downregulation of proliferation marker (Ki67) (P = 0.01), upregulation of carbonic anhydrase-9 (P = 0.04), upregulation of Hypoxia inducible factor 1 alpha (HIF1a) (P = 0.001) and down-regulation of plasmalemma vascular associated protein (PLVAP) (P = 0.02) in response to bevacizumab.